Induction of androgen receptor activity by norgestimate and norelgestromin in MDA-MB 231 breast cancer cells

Gynecological Endocrinology

Volumn 19, Issue 1, 2004, Pages 18-21

  Prifti, S ^a,b   Lelle, I ^a   Strowitzki, T ^a   Rabe, T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Androgen receptor; Luciferase activity; Norelgestromin; Norgestimate; Synthetic progestins

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; GESTAGEN; HYDROXYPROGESTERONE; LUCIFERASE; NORELGESTROMIN; NORGESTIMATE; TESTOSTERONE ACETATE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; DRUG EFFECT; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE CONSTRUCT; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; REPORTER GENE; TRANSACTIVATION;

17-ALPHA-HYDROXYPROGESTERONE; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, COMBINED; DIHYDROTESTOSTERONE; ETHISTERONE; GENETIC VECTORS; HUMANS; LUCIFERASES; NORGESTREL; OXIMES; RECEPTORS, ANDROGEN; TESTOSTERONE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 4444339957     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590410001728050     Document Type: Article

References (21)

1. Bubley GJ, Balk SP. Treatment of metastatic prostate cancer. Lessons from the androgen receptor. Hematol Oncol Clin North Am 1996;10:713-25
2. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3:95-103
3. Bentel JM, Birrell SN, Pickering MA, et al. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 1999;154:11-20
4. Rittmaster RS. Clinical relevance of testosterone and dihydrotestosterone metabolism in women. Am J Med 1995;98:17-21
5. Derman RJ. Androgen excess in women. Int J Fertil Menopausal Stud 1996;41:172-6
6. Burkman RT. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 1995;98:130-6
7. Gupta C, Bullock LP, Bardin CW. Further studies on the androgenic, anti-androgenic, and synandrogenic actions of progestins. Endocrinology 1978;102:736-44
8. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15
9. Collins D. Selectivity information on desogestrel. Am J Obstet Gynecol 1993;168:1010-6
10. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003;63:463-92
11. Rabe T, Bohlmann MK, Rehberger-Schneider S, Prifti S. Induction of estrogen receptor-α and -β activities by synthetic progestins. Gynecol Endocrinol 2000;14:118-26
12. Yamabe Y, Hoshino A, Imura N, et al. Enhancement of androgen-dependent transcription and cell proliferation by tributyltin and triphenyltin in human prostate cancer cells. Toxicol Appl Pharmacol 2000;169:177-84
13. Deckers GH, Schoonen WG, Kloosterboer HJ. Influence of the substitution of 11-methylene, delta (15), and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals. J Steroid Biochem Mol Biol 2000;74:83-92
14. Collins DC. Sex hormone receptor binding, progestin selectivity, and the new oral contraceptives. Am J Obstet Gynecol 1994;170:1508-13
15. Pajunen AE, Isomaa W, Jänne OA, et al. Androgenic regulation of ODC activity in mouse kidney and its relationship to changes in cytosol and nuclear androgen receptor concentrations. J Biol Chem 1982;257:8190-8
16. Schoonen WG, Deckers GH, de Gooijer ME, et al. Hormonal properties of norethisterone, 7α-methylnorethisterone and their derivatives. J Steroid Biochem Mol Biol 2000;74:213-22
17. Zhang Z, Lundeen SG, Zhu Y, et al. In vitro characterization of trimegestone: a new potent and selective progestin. Steroids 2000;65:637-43.
18. Di Monaco M, Leonardi L, Gatto V, et al. Dihydrotestosterone affects the growth of hormone-unresponsive breast cancer cells: an indirect action. Anticancer Res 1995;15:2581-4
19. Couzinet B, Young J, Brailly S, et al. The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor. J Clin Endocrinol Metab 1996;81:4218-23
20. Phillips A, Demarest K, Hahn DW. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 2000;41:399-410
21. Phillips A, Hahn DW, McGuire JL. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am J Obstet Gynecol 1992;167:1191-6